{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:18:23Z","timestamp":1761293903345,"version":"3.41.2"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2019.00191","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T01:25:55Z","timestamp":1553563555000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Perspectives of Induction With Chemo and\/or Immune Check Point Inhibition in Head and Neck Organ Preservation Treatment"],"prefix":"10.3389","volume":"9","author":[{"given":"Susanne","family":"Wiegand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnar","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1200\/JCO.2005.01.2047","article-title":"Single-cycle induction chemotherapy select patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm","volume":"24","author":"Urba","year":"2006","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1200\/JCO.2007.12.7597","article-title":"Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number","volume":"26","author":"Worden","year":"2008","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/cncr.29188","article-title":"Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: what are the best predictors of remission and prognosis?","volume":"121","author":"Semrau","year":"2015","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djp007","article-title":"Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation","volume":"101","author":"Pointreau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"B5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/annonc\/mdy332","article-title":"Induction chemotherapy. (IC) followed by radiotherapy. (RT) versus cetuximab plus IC and RT in advanced laryngeal\/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II","volume":"29","author":"Dietz","year":"2018","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejca.2016.11.013","article-title":"Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and 18F-FDG-PET\/CT","volume":"72","author":"Wichmann","year":"2017","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/lary.27011","article-title":"Meta-analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck","volume":"128","author":"Kiong","year":"2018","journal-title":"Laryngoscope"},{"key":"B9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/hed.21081","article-title":"Larynx preservation clinical trial design: key issues and recommendations\u2013a consensus panel summary","volume":"31","author":"Lefebvre","year":"2009","journal-title":"Head and Neck"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJM199106133242402","article-title":"The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer","volume":"324","author":"Wolf","year":"1991","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"MACH-NC Collaborative Group. meta-analysis of chemotherapy in head and neck cancer. (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1200\/JCO.2012.47.7802","article-title":"Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group","volume":"31","author":"Blanchard","year":"2013","journal-title":"J Clin Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3892\/mco.2018.1645","article-title":"Induction chemotherapy in patients with resectable laryngeal cancer: A meta-analysis","volume":"9","author":"Gao","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91\u201311: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.2018.77.8001","article-title":"Different view on larynx preservation evidence-based treatment recommendations","volume":"36","author":"Licitra","year":"2018","journal-title":"J Clin Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1200\/JCO.2018.77.8316","article-title":"Reply to L. Licitra et al","volume":"36","author":"Forastiere","year":"2018","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1016\/j.ejca.2015.08.007","article-title":"Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis","volume":"51","author":"Marta","year":"2015","journal-title":"Eur J Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov."},{"key":"B21","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.radonc.2015.10.014","article-title":"Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck. (HNSCC): a meta-analysis of randomized trials","volume":"118","author":"Budach","year":"2016","journal-title":"Radiother Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/PPO.0000000000000253","article-title":"Role of induction chemotherapy prior to chemoradiation in head and neck squamous cell cancer-systematic review and meta-analysis","volume":"23","author":"Vidal","year":"2017","journal-title":"Cancer J"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S1470-2045(18)30565-5","article-title":"No role for induction chemotherapy for head and neck cancers","volume":"19","author":"Venkatesan","year":"2018","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma. (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B27","article-title":"Abstract LBA8_PR","volume":"29","author":"Burtness","year":"2018","journal-title":"Ann Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/emboj.2012.333","article-title":"The cancer antigenome","volume":"32","author":"Heemskerk","year":"2013","journal-title":"EMBO J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMe1803923","article-title":"Fast forward \u2014 neoadjuvant cancer immunotherapy","volume":"378","author":"Gajewski","year":"2013","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1056\/NEJMc1808251","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"379","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"mdx440.041","DOI":"10.1093\/annonc\/mdx440.041","article-title":"An open-label, multicohort, phase 1\/2 study in patients with virus-associated cancers. (CheckMate 358): Safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma of the head and neck. (SCCHN)","volume":"28","author":"Ferris","year":"2017","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.6017","article-title":"Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma","volume":"36","author":"Wise-Draper","year":"2018","journal-title":"J Clin Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.1200\/JCO.2017.35.15_suppl.6012","article-title":"Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma. (HNSCC)","volume":"15","author":"Uppaluri","year":"2017","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1200\/JCO.2018.36.15_suppl.6068","article-title":"A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus. (HPV) positive and negative head and neck squamous cell carcinoma. (HNSCC)","volume":"36","author":"Ottensmeier","year":"2018","journal-title":"J Clin Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1200\/JCO.2018.36.15_suppl.6011","article-title":"Neoadjuvant anti-OX40. (MEDI6469) prior to surgery in head and neck squamous cell carcinoma","volume":"36","author":"Bell","year":"2018","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1470-2045(17)30421-7","article-title":"Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck. (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial","volume":"18","author":"Harrington","year":"2017","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1200\/JCO.2018.36.15_suppl.6013","article-title":"Health-related quality of life","volume":"36","author":"Cohen","year":"2018","journal-title":"J Clin Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00428-016-1910-4","article-title":"Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients","volume":"468","author":"Ilie","year":"2016","journal-title":"Virchows Arch"},{"key":"B39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD- 1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.oraloncology.2017.04.017","article-title":"HLA traits linked to development of head and neck squamous cell carcinoma affect the progression-free survival of patients","volume":"69","author":"Wichmann","year":"2017","journal-title":"Oral Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fonc.2018.00168","article-title":"Development of a human leukocyte antigen score to predict progression-free survival in head and neck squamous cell carcinoma patients","volume":"8","author":"Wichmann","year":"2018","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/sj.bjc6605465","article-title":"Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses","volume":"102","author":"Liu","year":"2010","journal-title":"Br J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","article-title":"Regulation of PD-L1: a novel role of pro-survival signaling in cancer","volume":"27","author":"Chen","year":"2016","journal-title":"Ann Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/0008-5472.CAN-14-3098","article-title":"Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-\u03baB to foster an immunosuppressive tumor microenvironment in ovarian cancer","volume":"75","author":"Peng","year":"2015","journal-title":"Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/cas.13072","article-title":"The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo- adjuvant chemotherapy","volume":"107","author":"Zhang","year":"2016","journal-title":"Cancer Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"8521","DOI":"10.1200\/JCO.2018.36.15_suppl.8521","article-title":"Neoadjuvant chemo\/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer. (NSCLC): a phase II multicenter exploratory study\u2014NADIM study-SLCG","volume":"36","author":"Provencio-Pulla","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00191\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T01:25:56Z","timestamp":1553563556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00191\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":48,"alternative-id":["10.3389\/fonc.2019.00191"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2019.00191","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"article-number":"191"}}